Request to Join
has invited you to join this group
Dr. Ridker serves as the Eugene Braunwald Professor of Medicine at the Harvard Medical School and directs the Center for Cardiovascular Disease Prevention, a translational epidemiologic research unit at the Brigham and Women’s Hospital in Boston focused on inflammatory mechanisms of atherosclerosis, population biology, genetic epidemiology, and the biology of innate immunity and vascular inflammation as it relates to cardiovascular disease and atherosclerosis. Among many ongoing multi-national projects, Dr. Ridker currently serves as Trial Chairman of the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) and the NIH-sponsored Cardiovascular Inflammation Reduction Trial (CIRT), two large-scale outcome trials seeking to address whether reducing inflammation without altering LDL cholesterol can reduce vascular event rates. The recipient of numerous awards and honorary degrees, Dr. Ridker has had continuous investigator initiated RO1 grant support from the NIH throughout his career and, with Professor Julie Buring, directs a T32 training program in Cardiovascular Epidemiology which is in its 26 th year. He is the author of over 800 peer reviewed publications and has an H-index greater than 170. Dr. Ridker serves on multiple national committees including the Board of External Experts for the National Heart Lung and Blood Institute.
Brendan M. Everett, MD, MPH is an Assistant Professor at Harvard Medical School and Associate Physician and Director of the Inpatient General Cardiology Service at the Brigham and Women’s Hospital in Boston, Massachusetts. Dr. Everett is a general cardiologist with a clinical and research interest in the primary and secondary prevention of cardiovascular disease, as well as the use of novel biomarkers in cardiovascular disease. He has an active clinical practice at the Brigham and Women’s Hospital focused on the prevention cardiovascular disease. Dr. Everett serves as the Chair of the Clinical Endpoints Committee for CANTOS, and as the Endpoints Committee Chair for a number of other ongoing NIH- and industry-funded clinical trials in cardiovascular medicine, including the ongoing multi-national CIRT and PROMINENT trials. Dr. Everett serves on the FDA’s Endocrinologic and Metabolic Advisory Committee, and has an active research portfolio examining the epidemiology, genetics, and biology of cardiovascular disease.